Comprehensive characterization of genomic and radiologic features reveals distinct driver patterns of <scp>RTK</scp>/<scp>RAS</scp> pathway in ground‐glass opacity pulmonary nodules

Yu, Fenglei; Peng, Muyun; Bai, Jing; Zhu, Xiuli; Zhang, Bingyu; Tang, Jingqun; Li, Wenliang; Chen, Chen; Wang, Xiang; Chen, Mingjiu; Tan, Sichuang; Sun, Yi; Liang, Qingchun; Li, Jina; Hu, Yan; Liao, Aihui; Hu, Huali; He, Yu; Xiao, Xiao; Wang, Bin; Xing, Guoming; Xu, Yaping; Chen, Rongrong; Xia, Xuefeng; Chen, Xiaofeng

doi:10.1002/ijc.34238

Cited by 4 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, research has demonstrated that, as the GGN solid component increases, the mutation frequency of EGFR , KRAS and TP53 increases ( 93 ). Notably, KRAS mutations are associated with a higher rate of CD8 + T cell infiltration, stronger proliferative and immunosuppressive signals ( 92 , 102 , 104 ). ALK mutations are more frequently observed in young adults and are mainly diagnosed at an advanced tumor stage ( 100 , 105 , 106 ).…”

Section: Genomic Characterization Of Sub-centimeter Lung Cancermentioning

confidence: 99%

Advancements in the diagnosis and treatment of sub‑centimeter lung cancer in the era of precision medicine (Review)

Wang,

Shi,

Liu

2024

Mol Clin Oncol

View full text Add to dashboard Cite

Lung cancer is the malignancy with the highest global mortality rate and imposes a substantial burden on society. The increasing popularity of lung cancer screening has led to increasing number of patients being diagnosed with pulmonary nodules due to their potential for malignancy, causing considerable distress in the affected population. However, the diagnosis and treatment of sub-centimeter grade pulmonary nodules remain controversial. The evolution of genetic detection technology and the development of targeted drugs have positioned the diagnosis and treatment of lung cancer in the precision medicine era, leading to a marked improvement in the survival rate of patients with lung cancer. It has been established that lung cancer driver genes serve a key role in the development and progression of sub-centimeter lung cancer. The present review aimed to consolidate the findings on genes associated with sub-centimeter lung cancer, with the intent of serving as a reference for future studies and the personalized management of sub-centimeter lung cancer through genetic testing.

show abstract

Section: Genomic Characterization Of Sub-centimeter Lung Cancermentioning

confidence: 99%

Advancements in the diagnosis and treatment of sub‑centimeter lung cancer in the era of precision medicine (Review)

Wang,

Shi,

Liu

2024

Mol Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Deciphering the driving factors underlying this process is of paramount importance as they hold potential diagnostic and therapeutic implications. Distinct gene mutations exhibit diverse biological behaviors, with studies demonstrating that EGFR and KRAS mutations are associated with aggressive and rapid growth of these nodules [51][52][53][54]. EGFR mutations represent the most prevalent and primary driving force behind early disease progression [51,55].…”

Section: Progress and Feasibility Of Targeted Therapymentioning

confidence: 99%

“…Distinct gene mutations exhibit diverse biological behaviors, with studies demonstrating that EGFR and KRAS mutations are associated with aggressive and rapid growth of these nodules [51][52][53][54]. EGFR mutations represent the most prevalent and primary driving force behind early disease progression [51,55]. Nodules harboring BRAF, ERBB2, and MAPK2P1 mutations exhibit an indolent behavior and a higher likelihood of being classified as partsolid ground-glass nodules [51], The absence of EGFR, KRAS, ALK and HER2 mutations was found to be associated with no growth in GGN.…”

Section: Progress and Feasibility Of Targeted Therapymentioning

confidence: 99%

“…EGFR mutations represent the most prevalent and primary driving force behind early disease progression [51,55]. Nodules harboring BRAF, ERBB2, and MAPK2P1 mutations exhibit an indolent behavior and a higher likelihood of being classified as partsolid ground-glass nodules [51], The absence of EGFR, KRAS, ALK and HER2 mutations was found to be associated with no growth in GGN. In addition, this study revealed a high incidence of EGFR mutations and a low incidence of KRAS mutations, which may be attributed to ethnic characteristics and other factors [54].…”

Section: Progress and Feasibility Of Targeted Therapymentioning

confidence: 99%

See 1 more Smart Citation

The diagnosis and management of multiple ground-glass nodules in the lung

Li,

Xiao,

et al. 2024

Eur J Med Res

View full text Add to dashboard Cite

The prevalence of low-dose CT (LDCT) in lung cancer screening has gradually increased, and more and more lung ground glass nodules (GGNs) have been detected. So far, a consensus has been reached on the treatment of single pulmonary ground glass nodules, and there have been many guidelines that can be widely accepted. However, at present, more than half of the patients have more than one nodule when pulmonary ground glass nodules are found, which means that different treatment methods for nodules may have different effects on the prognosis or quality of life of patients. This article reviews the research progress in the diagnosis and treatment strategies of pulmonary multiple lesions manifested as GGNs.

show abstract

“…Although multicentric origin was predominant, they also detected early metastatic events among multifocal SSNs. Similarly, Yu et al (78) performed a custom 1021-gene panel sequencing of 334 resected pulmonary nodules presenting as GGO from 262 Chinese patients. They compared gene pathways enriched in different GGOs (pure GGOs and mixed GGOs) through genomic profiling.…”

Section: The Distinction Between Mplc and Ipmmentioning

confidence: 99%

Multiple primary lung cancer: Updates of clinical management and genomic features

et al. 2023

View full text Add to dashboard Cite

In recent decades, multiple primary lung cancer (MPLC) has been increasingly prevalent in clinical practice. However, many details about MPLC have not been completely settled, such as understanding the driving force, clinical management, pathological mechanisms, and genomic architectures of this disease. From the perspective of diagnosis and treatment, distinguishing MPLC from lung cancer intrapulmonary metastasis (IPM) has been a clinical hotpot for years. Besides, compared to patients with single lung lesion, the treatment for MPLC patients is more individualized, and non-operative therapies, such as ablation and stereotactic ablative radiotherapy (SABR), are prevailing. The emergence of next-generation sequencing has fueled a wave of research about the molecular features of MPLC and advanced the NCCN guidelines. In this review, we generalized the latest updates on MPLC from definition, etiology and epidemiology, clinical management, and genomic updates. We summarized the different perspectives and aimed to offer novel insights into the management of MPLC.

show abstract

Comprehensive characterization of genomic and radiologic features reveals distinct driver patterns of RTK/RAS pathway in ground‐glass opacity pulmonary nodules

Cited by 4 publications

References 34 publications

Advancements in the diagnosis and treatment of sub‑centimeter lung cancer in the era of precision medicine (Review)

Advancements in the diagnosis and treatment of sub‑centimeter lung cancer in the era of precision medicine (Review)

The diagnosis and management of multiple ground-glass nodules in the lung

Multiple primary lung cancer: Updates of clinical management and genomic features

Contact Info

Product

Resources

About